Skip to main content

Randox Licenses Seegene Technology

NEW YORK (GenomeWeb News) – Randox Laboratories has agreed to a non-exclusive license for Seegene's technology for use with its biochip array platform, Seegene said today.

The agreement will give Randox access to Seegene's Dual Priming Oligo technology, which it will use to develop high-throughput diagnostic screening panels to detect a variety of pathogens that cause either respiratory or sexually transmitted diseases from one sample.

Randox's Biochip Array Technology is used to detect a panel of related biological markers. The panels include protein biochips for detecting antigens, DNA biochips for mutation, SNP studies and RNA expression profiling.

Financial terms of the agreement were not released.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.